ClinicalTrials.Veeva

Menu

Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans

The University of Texas System (UT) logo

The University of Texas System (UT)

Status

Enrolling

Conditions

PTSD

Treatments

Device: Transcranial magnetic stimulation (TMS)
Behavioral: Fear Conditioning and Extinction Paradigm

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05368987
R01MH125198 (U.S. NIH Grant/Contract)
HSC-MS-23-0426

Details and patient eligibility

About

This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS) impacts fear circuits. The overarching objectives are to understand how varying TMS parameters affect targeted brain regions in order to optimize its impact on enhancing fear extinction memory consolidation in a population with known fear extinction deficiencies: post-traumatic stress disorder (PTSD). 250 subjects will take part in this research study across UTHealth Houston. The study will include preliminary screenings, baseline visits, and experimental visits across four days

Full description

The experiments proposed are aimed to understand how timing and location of transcranial magnetic stimulation (TMS) in humans will impact their ability to reduce conditioned fear responses and impact the activation of their brain regions involved in fear regulation. The researchers will use a novel TMS approach to vary timing and location of its delivery so that the researchers can characterize and establish best time and location to obtain optimal impact on fear inhibition, and then test these parameters in PTSD patients and see if such can rescue extinction deficits in PTSD. The anticipated impact is to enhance our understanding of the neural mechanisms of associated with TMS use and explore potential novel approaches for advancing PTSD treatment.

Enrollment

250 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Willing and able to provide informed consent.
  • Inclusion Criteria for PTSD Subjects - Diagnosis of current PTSD
  • Inclusion Criteria: Healthy Controls (HC) - no current psychiatric disorders ("Axis I" disorders)

Exclusion criteria

  • Lifetime history of seizure or significant head trauma or other significant neurologic disease (e.g., tic disorder)
  • History of serious/significant psychiatric diagnoses ("Axis I" diagnoses)
  • Current significant suicidal ideation, plan or intent or suicidal behavior in past 6 months based on CSSRS and clinical judgment or Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily
  • Use of neuroleptics within one year prior to study
  • Current substance use
  • Pregnancy (to be ruled out by urine β-HCG).
  • Metallic implants or devices contraindicating magnetic resonance imaging.
  • Currently taking medications that lower the seizure threshold. These include antipsychotics, high dose theophylline or stimulants such as methylphenidate. Patients taking bupropion must be on a stable dose (*last 3 months) and take less than or equal to 300 mg/day.
  • Implanted devices in subject's head (shunts, cochlear implants); metal in subject's head (other than dental implants).
  • High risk of adverse emotional or behavioral reaction, and/or an inability to understand study procedures or the informed consent process
  • Additional exclusion criteria for Healthy controls (HC) group: Current psychiatric diagnosis ("Axis I" diagnosis)

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

250 participants in 1 patient group

Fear Conditioning and Extinction Paradigm, plus Transcranial Magnetic Stimulation (TMS)
Experimental group
Description:
Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day. On day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner. On day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day.
Treatment:
Behavioral: Fear Conditioning and Extinction Paradigm
Device: Transcranial magnetic stimulation (TMS)

Trial contacts and locations

1

Loading...

Central trial contact

Mohammed Milad, PhD; Isabel Moallem, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems